Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

133.21 +2.35 (+1.80%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

76 77 Next >

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

October 19, 2025

From Gilead Sciences, Inc.

Via Business Wire

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

October 19, 2025

From Gilead Sciences, Inc.

Via Business Wire

Uncover the latest developments among S&P500 stocks in today's session. ↗

October 17, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.

Via Chartmill

Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ ↗

October 12, 2025

Via Stocktwits

UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment ↗

October 17, 2025

NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication.

Via Benzinga

Which S&P500 stocks are moving on Friday? ↗

October 17, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge

October 17, 2025

In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market...

Via MarketMinute

Topics Retirement

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials ↗

October 15, 2025

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 studies with stable weight outcomes.

Via Benzinga

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

October 15, 2025

From Gilead Sciences, Inc.

Via Business Wire

Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families

October 13, 2025

Via Get News

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months ↗

October 13, 2025

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combination therapy.

Via Benzinga

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades' ↗

October 13, 2025

On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade.

Via Benzinga

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

October 13, 2025

From Gilead Sciences, Inc.

Via Business Wire

3 S&P 500 Stocks We Approach with Caution

October 10, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Intellectual Property Stocks

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

October 09, 2025

From Gilead Sciences, Inc.

Via Business Wire

Breaking Down Gilead Sciences: 6 Analysts Share Their Views ↗

October 08, 2025

Via Benzinga

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike ↗

October 08, 2025

The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.

Via Investor's Business Daily

Gilead Sciences Inc (NASDAQ:GILD) Presents a Compelling Case for Value Investors ↗

October 08, 2025

Gilead Sciences (GILD) presents a strong value investing case with a low P/E ratio, high profitability, and solid cash flow, suggesting the stock may be undervalued.

Via Chartmill

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

October 07, 2025

Via Benzinga

Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway ↗

October 06, 2025

The company stated that under the settlements, no generic entry is expected for Biktarvy in the United States before April 1, 2036.

Via Stocktwits

Topics Intellectual Property

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036 ↗

October 06, 2025

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036.

Via Benzinga

Topics Intellectual Property

Telecom Stocks Rattled After Verizon Unexpectedly Names Dan Schulman New CEO ↗

October 06, 2025

The appointment is effective immediately, replacing Hans Vestberg who has led Verizon since 2018.

Via Investor's Business Daily

Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump ↗

October 06, 2025

The company is well known for its HIV treatment, Biktarvy. Biktarvy accounted for more than two-thirds of Gilead's HIV June-quarter sales.

Via Investor's Business Daily

Topics Intellectual Property

Discover the top S&P500 movers in Monday's pre-market session. ↗

October 06, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.

Via Chartmill

2 Surefire Dividend Stocks to Buy for the Long Haul ↗

October 04, 2025

Both have crushed the market in 2025.

Via The Motley Fool

Topics Economy Government Intellectual Property

Is Gilead Sciences Inc Gaining or Losing Market Support? ↗

October 02, 2025

Via Benzinga

These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap ↗

October 02, 2025

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

Via Benzinga

Market Whales and Their Recent Bets on GILD Options ↗

October 02, 2025

Via Benzinga

2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off

October 01, 2025

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Via StockStory

Topics Credit Cards

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

76 77 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.